English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective To determine the predictors of the therapeutic effects of tocilizumab (TCZ) switched from other biologics with different mechanisms of action in rheumatoid arthritis (RA). Methods Patients who switched from tumor necrosis factor inhibitors (TNFis) or abatacept (ABT) to TCZ were analyzed. They were categorized into two groups based on clinical disease activity at week 24 (response group: 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR) (3) ≤ 3.2, and non-re‐ sponse group: DAS28-ESR (3) > 3.2). We compared DAS28-ESR (3) at the initiation of TCZ therapy (ΔDAS) in patients switching from TNFis and ABT. We examined whether the therapeutic effect of TCZ switched from TNFis and ABT could be predicted using clinical parameters. Results Sixty-seven patients were analyzed (TNFis, 53; ABT, 14); of these, 36 (67.9%) patients who re‐ ceived TNFis and 6 (42.9%) who were treated with ABT were considered responders. In patients who switched from TNFis, ΔDAS in the non-response group was significantly lower than that in the response group until week 8, and the improvement in the non-response group reached a plateau at week 12. Conversely, in patients treated with ABT, ΔDAS was significantly different between the response and non-response groups in the early phase, i.e., at week 4. In univariate regression analysis, ΔDAS at week 4 was correlated with DAS28-ESR (3) at week 24 (p < 0.05) in patients switching from ABT. Receiver operating characteristic analyses suggested that 0.74 was the optimal ΔDAS cutoff at week 4 to predict response vs. non-response at week 24 (sensitivity: 100%, specificity: 87.5%, p < 0.001). Conclusion The efficacy of TCZ may vary depending on which biologics were used previously. The effec‐ tiveness of TCZ switched from ABT could be predicted by the therapeutic response at week 4.

Early Response of DAS28-ESR (3) Predicts Sustained Response to Tocilizumab Switched from Abatacept